Oxytocin in labor and postpartum: uses, risks, evidence

Complete guide: Sexual health peptides: a complete guide to PT-141

What is oxytocin and what is it used for in childbirth?

Oxytocin is a nine-amino-acid peptide hormone. The synthetic drug used in obstetrics is described in the FDA label as a nonapeptide prepared synthetically to avoid contamination with vasopressin and other biologically active polypeptides⁴. It acts on specific receptors in the myometrium, whose concentration rises sharply in pregnancy and peaks in early labor at term, and its plasma half-life is about 1 to 6 minutes⁴.

The history of the class is told in A century of therapeutic peptides. This article covers two women's-health settings where approved peptides exist: postpartum hemorrhage and labor induction or augmentation. Intranasal oxytocin for behavior or emotions is a different subject with a different evidence base: see Intranasal oxytocin: anatomy of a replication crisis.

How common the problem is. WHO states that about 14 million women suffer postpartum hemorrhage every year, that it is the largest direct cause of maternal death, and that 99% of these deaths occur in low- and middle-income countries¹. A WHO systematic analysis of causes of maternal death in 2009-2020 estimated that hemorrhage is the most common cause (27%; 80% uncertainty interval 22 to 32), followed by indirect obstetric causes (23%) and hypertensive disorders (16%), with most hemorrhage deaths occurring postpartum³.

How postpartum hemorrhage is assessed and when labor is induced

Postpartum hemorrhage is assessed by the amount of bleeding and its clinical impact; trials and reviews commonly use thresholds of 500 ml and 1000 ml⁵⁶. Uterine atony, a uterus that fails to contract, is the mechanism targeted by drugs that produce uterine contraction. American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 183 summarizes the approach to postpartum hemorrhage¹³.

Labor induction is the artificial initiation of contractions. The ARRIVE trial, with 6,106 low-risk nulliparous women, compared induction at 39 weeks with expectant management: the composite perinatal outcome was 4.3% with induction and 5.4% with expectant management (RR 0.80; 95% CI 0.64 to 1.00), and cesarean delivery was less frequent with induction (18.6% vs 22.2%; RR 0.84; 95% CI 0.76 to 0.93)⁸. In 2022 WHO published recommendations on induction of labour at or beyond term, which supersede its previous recommendations on the topic¹⁴.

Standard treatment today: what guidelines recommend

Preventing postpartum hemorrhage. WHO recommends oxytocin as the uterotonic for preventing postpartum hemorrhage in all births where several options are available¹. Where oxytocin is not available or its quality cannot be guaranteed, WHO recommends carbetocin, and states that when the cold chain is poor, heat-stable uterotonics (carbetocin or misoprostol) are suitable options depending on context¹. The practical reason is that oxytocin needs cold storage, which is often unreliable in resource-constrained settings².

Active management of the third stage. The 2019 Cochrane review of active management (which includes a uterotonic, cord clamping and controlled cord traction) versus expectant management analyzed 8 studies and 8,892 women. Because high-quality evidence was absent, the authors use cautious language: active management reduces mean blood loss and probably reduces bleeding above 500 ml and the use of therapeutic uterotonics, although it may increase diastolic blood pressure, vomiting and afterpains¹¹.

Treating established hemorrhage. The 2020 Cochrane review (7 trials, 3,738 women) compared first-line uterotonics. Most women in the trials gave birth vaginally in hospital. Misoprostol as first-line treatment probably increases the risk of blood transfusion compared with oxytocin (RR 1.47; 95% CI 1.02 to 2.14; moderate certainty) and increases vomiting (RR 2.47; high certainty)⁷.

Inducing and augmenting labor. For augmentation when spontaneous labor progresses slowly, the 2013 Cochrane review (8 studies, 1,338 low-risk women) found no difference in cesarean or instrumental delivery with oxytocin versus no treatment or delayed treatment; early use shortened labor by about two hours but increased uterine hyperstimulation with fetal heart rate changes¹⁰.

What peptide research has shown: oxytocin and carbetocin

Oxytocin (FDA-approved). The Pitocin (oxytocin injection) label indicates it, antepartum, for initiating or improving uterine contractions when desirable and suitable for fetal or maternal reasons, including induction in patients with a medical indication, stimulation or reinforcement of labor in selected cases of uterine inertia, and adjunctive therapy in incomplete or inevitable abortion; postpartum, to produce contractions in the third stage of labor and control postpartum bleeding or hemorrhage⁴. The label adds that elective induction is not an indication, because available data are inadequate to evaluate the benefit-to-risk balance⁴. For induction with oxytocin, the 2014 Cochrane review of high- versus low-dose regimens (9 trials, 2,391 women, moderate to high risk of bias) found no significant differences in vaginal delivery not achieved within 24 hours (RR 0.94; 95% CI 0.78 to 1.14) or cesarean section (RR 0.96; 95% CI 0.81 to 1.14)⁹.

Carbetocin (a long-acting peptide oxytocin analogue). It is an oxytocin analogue with a heat-stable formulation studied for preventing postpartum hemorrhage. The WHO CHAMPION trial randomized 29,645 women at 23 sites in 10 countries, double blind, to intramuscular heat-stable carbetocin versus oxytocin immediately after vaginal birth. The first primary outcome (blood loss of at least 500 ml or use of additional uterotonics) was 14.5% with carbetocin and 14.4% with oxytocin (RR 1.01; 95% CI 0.95 to 1.06), consistent with noninferiority. For blood loss of at least 1000 ml it was 1.51% vs 1.45% (RR 1.04; 95% CI 0.87 to 1.25), with an interval crossing the noninferiority margin, which the authors attributed to the low event rate; the trial was funded by Merck Sharp & Dohme⁵. WHO reported that this formulation keeps its efficacy for at least 3 years at 30 °C and 75% relative humidity².

In the 2025 Cochrane review, carbetocin had effects similar to oxytocin for blood loss of at least 500 ml (high certainty) and little or no difference for at least 1000 ml (moderate certainty); for additional uterotonics the RR was 0.74 (95% CI 0.59 to 0.94; low certainty), and for transfusion there was no difference (moderate certainty)⁶. A randomized sub-study nested in CHAMPION at one hospital in India (1,799 women) found slightly lower postpartum hemoglobin with carbetocin (10.09 vs 10.21 g/dL; p = 0.0432) and a higher proportion with a hemoglobin drop of 2 g/dL or more (RR 1.29; 95% CI 1.02 to 1.63)¹⁵. As to regulatory status, carbetocin was not found in the Drugs@FDA data queried through the public openFDA API¹⁶.

On the excess-oxytocin hypothesis. A matched case-control study of women with severe postpartum hemorrhage from atony who received a transfusion compared oxytocin exposure during labor with controls: the area under the curve was 10,054 mU in cases and 3,762 mU in controls (p < 0.001), and the association persisted after adjusting for variables such as body mass index, induction, magnesium therapy and chorioamnionitis¹². This is an observational design: it shows an association, not that oxytocin causes atony.

Safety: adverse effects and contraindications

The FDA label for oxytocin warns that, for induction or augmentation of labor, it should be given only by the intravenous route with adequate medical supervision in a hospital, with continuous observation by trained personnel⁴. Antepartum contraindications include significant cephalopelvic disproportion, fetal positions undeliverable without conversion, fetal distress without imminent delivery, a hyperactive or hypertonic uterus, total placenta previa, vasa previa, cord prolapse and hypersensitivity to the drug⁴.

Reported maternal adverse reactions include anaphylactic reaction, arrhythmias, postpartum hemorrhage, pelvic hematoma, subarachnoid hemorrhage, fatal afibrinogenemia, hypertensive episodes, nausea, vomiting and uterine rupture; in the fetus or neonate, bradycardia, low Apgar scores at five minutes, neonatal jaundice, retinal hemorrhage, neonatal seizures, permanent brain damage and fetal death⁴. Because of its intrinsic antidiuretic effect, the label warns of possible water intoxication, with convulsions and coma and one maternal death described with prolonged slow infusions⁴.

For preventing postpartum hemorrhage, the 2025 Cochrane review found that all uterotonics compared, except carbetocin, were associated with more side effects than oxytocin⁶. In CHAMPION, adverse events did not differ significantly between carbetocin and oxytocin⁵.

Summary by drug

Frequently asked questions

Is oxytocin approved for childbirth? Yes. The FDA label for oxytocin injection indicates it for inducing or reinforcing labor when there is a medical reason and for producing contractions and controlling bleeding postpartum; it is not indicated for elective induction⁴.

What does WHO recommend to prevent postpartum hemorrhage? WHO recommends oxytocin for all births where several options are available and carbetocin where oxytocin is not available or its quality cannot be guaranteed¹.

Is carbetocin better than oxytocin? Not in general: in CHAMPION it was noninferior for the outcome of 500 ml or additional uterotonics, but noninferiority was not shown for 1000 ml⁵, and the 2025 Cochrane review describes similar effects for blood loss of at least 500 ml with high certainty⁶.

Is carbetocin approved by the FDA? It was not found in the Drugs@FDA data queried through openFDA¹⁶. WHO does include it in its recommendations for preventing postpartum hemorrhage in the settings mentioned¹.

Why does the cold chain matter? WHO notes that oxytocin needs cold storage and is unstable at room temperature, which is hard to guarantee in resource-constrained settings, and that is the rationale for the heat-stable carbetocin formulation².

Does induction at 39 weeks reduce cesareans? In ARRIVE, in low-risk nulliparous women, cesarean delivery was less frequent with induction (18.6% vs 22.2%), although the composite perinatal outcome was not significantly lower⁸.